key: cord-0703484-jjf11m2g
authors: Calò, Lorenzo A; Bertoldi, Giovanni; Davis, Paul A.
title: Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter’s and Gitelman’s syndrome patients
date: 2020-05-13
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.104903
sha: 0cab6f7487c454c6ce68b1ada7976a339c1fd0a1
doc_id: 703484
cord_uid: jjf11m2g

[Figure: see text]

. This suggests that increased ACE2 and reduced Rho kinase activity likely provide benefits in terms of reduced risk of COVID-19 such as those we found in Gitelman and Bartter's patients.

Our findings therefore support Abedy and coworkers' [2] call for human clinical trials to confirm their hypothesis regarding the benefits of ACE2 increases driven by Rho kinase inhibitors with respect to protection against the respiratory complications associated with SARS-CoV-2 infection.

Declaration of interests ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acute Lung Injury: the therapeutic role of Rho kinase inhibitors

Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)

Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter's and Gitelman's syndromes, human models of endogenous angiotensin II signaling antagonism

ROCK (RhoA/Rho kinase) in cardiovascular-renal pathophysiology: a review of new advancements

ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications

Angiotensin II type 1 receptor blockers and risk of COVID 19. Information from Bartter's and Gitelman's syndromes patients

This study was supported in part by DOR1935894/19 from University of Padova, to L.A.C.J o u r n a l P r e -p r o o f